BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19633648)

  • 21. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
    Samaratunga H; Duffy D; Yaxley J; Delahunt B
    Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type.
    Au S; Villamil CF; Alaghehbandan R; Wang G
    Ann Diagn Pathol; 2019 Apr; 39():59-62. PubMed ID: 30772651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features.
    Thompson ED; Wood LD
    Arch Pathol Lab Med; 2020 Jul; 144(7):808-815. PubMed ID: 31869246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers.
    Tarján M; Chen HH; Tot T; Wu W; Lenngren A; Dean PB; Tabár L
    Scand J Urol Nephrol; 2012 Aug; 46(4):258-66. PubMed ID: 22519924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
    Herawi M; Epstein JI
    Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma.
    Iakymenko OA; Lugo I; Kwon D; Zhao W; Hayee A; Punnen S; Parekh DJ; Pollack A; Ritch CR; Gonzalgo ML; Stoyanova R; Jorda M; Kryvenko ON
    Urology; 2020 Mar; 137():108-114. PubMed ID: 31711982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.
    Shi C; Hong SM; Lim P; Kamiyama H; Khan M; Anders RA; Goggins M; Hruban RH; Eshleman JR
    Mol Cancer Res; 2009 Feb; 7(2):230-6. PubMed ID: 19208745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas.
    Benhamida JK; Vyas M; Tanaka A; Wang L; Bahrami A; Ozcan K; Basturk O; Villafania L; Mata DA; El Jabbour T; Selenica P; Roehrl MHA; Weigelt B; Reis-Filho JS; Scaltriti M; Klimstra DS
    Mod Pathol; 2022 Jul; 35(7):956-961. PubMed ID: 34969956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Lindh C; Samaratunga H; Delahunt B; Bergström R; Chellappa V; Yaxley J; Lindberg J; Egevad L
    Prostate; 2022 Apr; 82(5):576-583. PubMed ID: 35049068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing.
    Zara Rozalen A; Martin JM; Rajendran R; Jain M; Nava VE
    Curr Oncol; 2024 Mar; 31(3):1556-1561. PubMed ID: 38534951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical characteristics of prostatic adenocarcinoma with ductal features].
    Yamashita R; Matsuzaki M; Matsui T; Yamaguchi R; Yuen K; Niwakawa M; Tobisu K
    Nihon Hinyokika Gakkai Zasshi; 2008 Mar; 99(3):525-30. PubMed ID: 18404881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Tan YG; Khalid F; Huang HH; Chen K; Tay KJ; Lau WKO; Cheng CWS; Ngo NT; Yuen JSP
    Prostate; 2021 Mar; 81(4):242-251. PubMed ID: 33428259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63.
    Torres A; Alshalalfa M; Davicioni E; Gupta A; Yegnasubramanian S; Wheelan SJ; Epstein JI; De Marzo AM; Lotan TL
    Prostate; 2018 Sep; 78(12):896-904. PubMed ID: 29761525
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology and genetics of pancreatic neoplasms with acinar differentiation.
    Wood LD; Klimstra DS
    Semin Diagn Pathol; 2014 Nov; 31(6):491-497. PubMed ID: 25441307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents.
    Grippo PJ; Sandgren EP
    Int J Cancer; 2012 Sep; 131(5):1243-8. PubMed ID: 22024988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acinar cell cystadenocarcinoma of the pancreas: report of rare case and review of the literature.
    Colombo P; Arizzi C; Roncalli M
    Hum Pathol; 2004 Dec; 35(12):1568-71. PubMed ID: 15619219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma.
    Kim A; Kwon T; You D; Jeong IG; Go H; Cho YM; Hong JH; Ahn H; Kim CS
    J Korean Med Sci; 2015 Apr; 30(4):385-9. PubMed ID: 25829805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.
    Zhu J; Nie S; Wu J; Lubman DM
    J Proteome Res; 2013 Jun; 12(6):2791-804. PubMed ID: 23679566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.